Dashboard E. coli
Repurposing candidates for E. coli
Escherichia coli
Approved medicines with AI-predicted activity ≥40% against E. coli, leaving out medicines that are already antimicrobials. Each is shown with what it is already used for. They are surfaced computationally for further investigation, not as treatments.
- AI-predicted activity ≥40%
- 467
- Existing antimicrobials set aside
- 103
- Needing review
- 28
- Repurposing candidates
- 336
Repurposing candidates for E. coli
AI prediction · nothing measuredAll 336 repurposing candidates for E. coli.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Baloxavir MarboxilExisting use: Influenza, Viral disease46.3% AI-predicted activityagainst E. coli24 registered studies
- LetermovirExisting use: Cytomegalovirus infection, Infection, Viral disease46.2% AI-predicted activityagainst E. coli50+ registered studies
- Gilteritinib FumarateExisting use: Acute myeloid leukemia, Myeloid leukemia, Neoplasm46.2% AI-predicted activityagainst E. coli3 registered studies
- GrazoprevirExisting use: Chronic hepatitis C virus infection46.2% AI-predicted activityagainst E. coli50+ registered studies
- PaliperidoneExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more46.2% AI-predicted activityagainst E. coli50+ registered studies
- BrinzolamideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma46.2% AI-predicted activityagainst E. coli50+ registered studies
- SelpercatinibExisting use: Cancer, Medullary thyroid gland carcinoma, Neoplasm and 4 more46.2% AI-predicted activityagainst E. coli42 registered studies
- Alectinib HydrochlorideExisting use: Cancer, Neoplasm, Non-small cell lung carcinoma46.1% AI-predicted activityagainst E. coli13 registered studies
- Neratinib MaleateExisting use: Breast cancer, Breast carcinoma, Breast neoplasm46.1% AI-predicted activityagainst E. coli7 registered studies
- Leniolisib PhosphateExisting use: Inborn error of immunity46.0% AI-predicted activityagainst E. coliNo documented evidence found
- Quetiapine FumarateExisting use: Bipolar disorder, Bipolar I disorder, Bipolar II disorder and 4 more46.0% AI-predicted activityagainst E. coli50+ registered studies
- ZafirlukastExisting use: Airway obstruction, Asthma45.9% AI-predicted activityagainst E. coli6 registered studies
- CangrelorExisting use: Myocardial infarction, Percutaneous Coronary Intervention, Recurrent thrombophlebitis45.9% AI-predicted activityagainst E. coli45 registered studies
- IloperidoneExisting use: Psychosis, Schizophrenia45.8% AI-predicted activityagainst E. coli32 registered studies
- Thiethylperazine MalateExisting use: Allergic disease45.8% AI-predicted activityagainst E. coliNo documented evidence found
- Fostamatinib DisodiumExisting use: Autoimmune thrombocytopenic purpura, Hemorrhage, Thrombocytopenia45.7% AI-predicted activityagainst E. coli27 registered studies
- DocetaxelExisting use: Adenocarcinoma, Breast cancer, Breast carcinoma and 19 more45.7% AI-predicted activityagainst E. coli50+ registered studies
- Fedratinib HydrochlorideExisting use: Myelofibrosis, Myeloproliferative disorder, Neoplasm and 1 more45.6% AI-predicted activityagainst E. coliNo documented evidence found
- IvabradineExisting use: Angina pectoris, Cardiovascular disease, Congestive heart failure and 1 more45.5% AI-predicted activityagainst E. coli50+ registered studies
- Pimavanserin TartrateExisting use: Hallucinations, Parkinson disease, Psychosis45.4% AI-predicted activityagainst E. coli46 registered studies
- Isavuconazonium SulfateExisting use: Aspergillosis, Mucormycosis45.2% AI-predicted activityagainst E. coli50+ registered studies
- RescinnamineExisting use: Hypertension45.2% AI-predicted activityagainst E. coliNo documented evidence found
- EluxadolineExisting use: Diarrheal disease, Irritable bowel syndrome45.1% AI-predicted activityagainst E. coli10 registered studies
- Ozanimod HydrochlorideExisting use: Multiple sclerosis, Relapsing-remitting multiple sclerosis, Ulcerative colitis45.0% AI-predicted activityagainst E. coli7 registered studies